Heikki Koski, currently the Service Business and Development Director at Tamro, has been appointed as the CEO of Medaffcon Oy, effective from April 1, 2024. Medaffcon is a subsidiary of Tamro Oyj. The current CEO of Medaffcon, Jarmo Hahl, will continue to play a pivotal role in shaping the company’s future in his new position leading the consulting business.
Medaffcon offers research and expert services tailored to the needs of the pharmaceutical industry and healthcare, focusing particularly on evaluating effectiveness and developing and utilizing research methods based on health information. The company aims to extend its expertise and knowledge beyond Finland’s borders.
“Jarmo has done commendable work leading Medaffcon since 2010 and has, with his strong expertise, laid the foundation for future growth with his team. We see this as the right moment to expand the business, focusing on both domestic operations and internationalization,” says Kai Kaasalainen, CEO of Tamro.
“I have had the pleasure of working with the Medaffcon team to develop the company’s operations for over three years, and I am delighted to continue this work as CEO. Medaffcon has an excellent team and expertise, highly satisfied customers, and all the prerequisites to successfully implement a new strategy for international growth,” says Heikki Koski.
Medaffcon Oy, founded in 2009, provides research, expert services and consultancy to meet the needs of the pharmaceutical industry and healthcare sector. Our services combine strong medical and health economics expertise with modern data science. Our key areas of expertise are Real-World Evidence (RWE) research based on real-life data, as well as medical and market access expert and consulting services. The quality and scope of Medaffcon’s services are built on high-level content and process expertise, alongside a strong collaboration network within the pharmaceutical industry, healthcare, academia, and research communities.
Medaffcon operates in Finland and Sweden, and through collaboration networks in other Nordic countries. The company employs about 30 experts.
Since 2017, Medaffcon has been a subsidiary of Tamro Oyj and is part of the PHOENIX group, which is a leading provider of healthcare services in Europe.
Learn more: medaffcon.fi/en
Contact details:
Heikki Koski
CEO
Medaffcon Oy
+358 44 251 7840
heikki.koski@medaffcon.fi
Despite its high-risk nature and availability of kidney treatments, chronic kidney disease (CKD) often goes undiagnosed. This especially concerns patients without type 2 diabetes (T2D), who represent the majority of CKD patients. This finding comes from a recent registry study published in Nephrology Dialysis Transplantation (NDT).
Artificial intelligence (AI) is transforming research and working life across various industries. But what is its significance in health data analysis and real-world evidence (RWE) research? Medaffcon’s experts, Juhani Aakko and Lisse-Lotte Hermansson, share their perspectives on AI in their work.
Patient-centricity was one of the key themes at ISPOR Europe in Barcelona this November. Participants also discussed topics such as the use of Real-World Evidence (RWE) in Health Technology Assessment (HTA) and the significance of artificial intelligence. In this article, Medaffcon's ISPOR attendees share the most important themes from this year's event.